Automate Your Wheel Strategy on MRNA
With Tiblio's Option Bot, you can configure your own wheel strategy including MRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRNA
- Rev/Share 8.1839
- Book/Share 26.0777
- PB 1.1335
- Debt/Equity 0.074
- CurrentRatio 4.2182
- ROIC -0.3311
- MktCap 11432093520.0
- FreeCF/Share -10.4249
- PFCF -2.841
- PE -3.3989
- Debt/Assets 0.0586
- DivYield 0
- ROE -0.301
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRNA | Citigroup | -- | Neutral | -- | $40 | March 13, 2025 |
| Downgrade | MRNA | Barclays | Overweight | Equal Weight | $111 | $45 | Feb. 18, 2025 |
| Downgrade | MRNA | Goldman | Buy | Neutral | $99 | $51 | Jan. 29, 2025 |
| Downgrade | MRNA | Argus | Buy | Hold | -- | -- | Dec. 18, 2024 |
| Resumed | MRNA | BofA Securities | -- | Underperform | -- | $41 | Dec. 10, 2024 |
| Initiation | MRNA | Bernstein | -- | Market Perform | -- | $55 | Oct. 17, 2024 |
| Downgrade | MRNA | Jefferies | Buy | Hold | $120 | $65 | Sept. 13, 2024 |
| Downgrade | MRNA | JP Morgan | Neutral | Underweight | $88 | $70 | Sept. 13, 2024 |
| Downgrade | MRNA | Oppenheimer | Outperform | Perform | -- | -- | Sept. 13, 2024 |
| Upgrade | MRNA | HSBC Securities | Reduce | Hold | -- | $82 | Aug. 28, 2024 |
News
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
Read More
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director Stephen Hoge - President Conference Call Participants Courtney Breen - Sanford C.
Read More
Moderna slashes full-year sales outlook, reduces headcount
Published: August 01, 2025 by: Proactive Investors
Sentiment: Negative
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares fell almost 9% in early trade as the pharmaceutical giant lowered its full-year guidance and announced a workforce reduction, overshadowing a Q2 earnings beat. The company lowered its 2025 revenue outlook by $300 million to a range of $1.5 billion to $2.2 billion, attributed to shipment timing.
Read More
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
Published: August 01, 2025 by: Investopedia
Sentiment: Negative
Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
Read More
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago.
Read More
Curious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Negative
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
Read More
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Read More
EU regulator backs Moderna's updated COVID vaccine
Published: July 25, 2025 by: Reuters
Sentiment: Positive
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday.
Read More
Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.
Read More
This Former Meme Stock, Down 93%, is a High-Upside Buy Right Now
Published: July 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago.
Read More
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.
Read More
Moderna Stock Gains on Encouraging Flu Vaccine Data
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
Read More
Top Stock Movers Now: Hewlett Packard Enterprise, Moderna, Tesla, and More
Published: June 30, 2025 by: Investopedia
Sentiment: Positive
U.S. equities gained at midday, with the S&P 500 and Nasdaq adding to their all-time highs, on optimism about more U.S. trade deals. The Dow Jones Industrial Average was up as well.
Read More
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
Published: June 30, 2025 by: WSJ
Sentiment: Positive
The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Read More
Moderna (MRNA) Advances While Market Declines: Some Information for Investors
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, Moderna (MRNA) closed at $25.90, indicating a +1.97% shift from the previous trading day.
Read More
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S. Health Secretary Robert F. Kennedy Jr. fired all members of an expert vaccine panel late on Monday.
Read More
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference Transcript
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Hi, everyone. Thank you.
Read More
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
Read More
Moderna, favored by the first Trump administration for its Covid-19 vaccine, is now in trouble as Trump 2.0 shifts its position on vaccine-making
Published: June 02, 2025 by: WSJ
Sentiment: Negative
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
Read More
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost-cutting, pipeline focus, and realistic revenue guidance after overreaching post-pandemic and burning through cash on speculative projects. Despite leadership changes at HHS and FDA and loss of government funding, Moderna could outperform 2025 guidance if vaccination rates and combo shots gain traction.
Read More
Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More
Published: June 02, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were mixed at midday after China hit back at the U.S. and accused Washington of violating a trade deal the two countries reached last month. President Donald Trump said on Friday that China had "totally violated" the truce they struck in Geneva.
Read More
Moderna moves higher on FDA approval of new COVID-19 vaccine
Published: June 02, 2025 by: Proactive Investors
Sentiment: Positive
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares edged higher after the US Food and Drug Administration (FDA) approved its newest COVID-19 vaccine mNEXSPIKE (mRNA-1283). The vaccine was approved for use in adults aged 65 and older and individuals aged 12 to 64 who have at least one underlying health risk factor as defined by the Centers for Disease Control and Prevention (CDC), Moderna said on Monday.
Read More
Moderna Stock Is Rising. A New Covid Vaccine Is Coming for Some People.
Published: June 02, 2025 by: Barrons
Sentiment: Positive
Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.
Read More
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals
Published: June 02, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.'s MRNA mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).
Read More
Moderna, Inc. (MRNA) Bernstein 41st Annual Strategic Decisions Conference Call Transcript
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ET Company Participants Stephane Bancel - CEO & Director Conference Call Participants Courtney Breen - Bernstein Courtney Breen So I am thrilled to be here today with Stephane Bancel from Moderna. My name is Courtney Breen.
Read More
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 27, 2025 by: Schaeffers Research
Sentiment: Neutral
Our volatility scorecard has a pretty good feel for the market right now.
Read More
About Moderna, Inc. (MRNA)
- IPO Date 2018-12-07
- Website https://www.modernatx.com
- Industry Biotechnology
- CEO Stephane Bancel
- Employees 5800